Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, UK.
Department of Haemato-Oncology, St Bartholomew's Hospital, London, UK.
Hematol Oncol Clin North Am. 2020 Aug;34(4):701-714. doi: 10.1016/j.hoc.2020.02.006. Epub 2020 Apr 16.
A subset of follicular lymphoma patients with high-risk clinical features continues to pose a therapeutic challenge. Hematopoietic stem cell transplantation is a suitable consolidative treatment option for these patients. Data on chimeric antigen receptor T-cell therapy are promising in relapsed/refractory and transformed patients. The increasing armamentarium of nontransplant options coupled with the associated potential long-term sequelae of transplantation raises questions about the placement of transplant strategies in the follicular lymphoma treatment hierarchy.
一部分滤泡性淋巴瘤患者具有高危临床特征,这仍然是一个治疗挑战。造血干细胞移植是这些患者合适的巩固治疗选择。嵌合抗原受体 T 细胞疗法在复发/难治性和转化患者中的数据很有前景。非移植选择的手段不断增加,加上移植相关的潜在长期后果,这引发了关于滤泡性淋巴瘤治疗分层中移植策略定位的问题。